Diamine derivatives as inhibitors of leukotriene A4 hydrolase

A method of treating a disease or disorder ameliorated by the inhibition of LTA4-h activity in a mammal, wherein the disease or disorder is selected from the group consisting of neurodegeneration in stroke, Alzheimer's disease, Parkinson's disease, encephalitis, HIV dementia, neuropathic pain, multiple sclerosis, and migraine, and wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of compound having Formula (I):

• wherein:
• R is the group
• n1, n2, and n3 are each independently 0 to 2;
• r is 0 to 4;
• q is 0 to 2;
• R1v, R1w, R1x, R1y and R1z are each independently hydrogen or fluoro;
• R2 and R7, together with the nitrogens to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
• or R2 and R7, together with the nitrogens to which they are attached and one of R5a, R5b and R5c, form an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
• or R2 and R5a, together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
• or R2 and R5b, together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
• R3 is —O—, —R12—O—, or —O—R12—;
• R4 is a direct bond, or an optionally substituted straight or branched alkylene chain;
• each R5a, R5b, R5c, R6a, R6b and R6c are each independently hydrogen, alkyl, haloalkyl or hydroxyalkyl;
• or any one of R5a and R6a together, R5b and R6b together, and R5c and R6c together can be an oxo group;
• R7 is hydrogen, —R13—OR10, —R13—C(═O)R10, —R13—C(═O)OR10, —R13—C(═O)—R13—N(R10)R11, —R13—N(R10)C(═O)N(R10)R11, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, or optionally substituted heterocyclylalkyl;
• R8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of halo, nitro, cyano, optionally substituted heteroaryl, hydroxyiminoalkyl, —R13—OR10, —R13—C(═O)R10, —R13—C(═O)OR10, —R13—C(═O)—R13—N(R10)R11, —R13—C(═O)N(R10)—R14—N(R10)R11, —R13—S(═O)tN(R10)R11 (where t is 1 or 2), —R13—N(R10)R11, —R13—N(R10)C(═O)R10, —R13—N(R10)C(═O)—R13—N(R10)R11, —R13—N(R10)—R13—C(═O)OR10, —R13—N(R10)C(═O)—R14—S(═O)tN(R10)R11 (where t is 1 or 2), —R13—N(R10)C(═O)—R13—N(R10)C(═O)R10, —R13—N(R10)C(═O)—R13—N(R10)—R14—N(R10)R11, —R13—N(R10)S(═O)tN(R10)R11 (where t is 1 or 2), and —R13—O—R14—C(═O)OR10;
• each R9 is independently —O—R10, alkyl, hydroxyalkyl, halo, haloalkyl, aryl or aralkyl;
• each R10 and R11 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
• or R10 and R11, together with the nitrogen to which they are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl;
• R12 is an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
• each R13 is independently a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
• and
• each R14 is independently an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
• as a single stereoisomer or as a mixture of stereoisomers;
• or a pharmaceutically acceptable thereof.